Reversal of P-glycoprotein-mediated multidrug resistance in vitro by doramectin and nemadectin

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 3, 2010, Pages 393-399

  Gao, Aili ^a   Wang, Xiangjing ^a   Xiang, Wensheng ^a   Liang, Hongsheng ^b   Gao, Jiguo ^a   Yan, Yijun ^a  

^a NORTHEAST AGRICULTURAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Doramectin; Multidrug resistance; Nemadectin; P glycoprotein

Indexed keywords

DORAMECTIN; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; NEMADECTIN; RHODAMINE 123;

ARTICLE; BREAST CARCINOMA; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION;

ABSORPTION; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; HUMANS; INHIBITORY CONCENTRATION 50; IVERMECTIN; MACROLIDES; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHODAMINE 123; RNA, MESSENGER;

EID: 77950192396     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.62.03.0016     Document Type: Article

References (30)

1. Maliepaard, M, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999 59 : 4559 4563.
2. Thomas, H. Coley, HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 2003 10 : 159 165.
3. Sikic, BI, et al. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997 40 : S13 S19.
4. Perloff, MD, et al. Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells. J Pharm Pharmacol 2007 59 : 947 953.
5. Liu YH et al. Multidrug resistance associated proteins and implications in drug development. Clin Exp Pharmacol Physiol 2009 Jun [Epub ahead of print 2008 1 : 93 105.
6. Zhou, Y, et al. Cepharanthine is a potent reversal agent for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol 2009 77 : 993 1001.
7. Elliott, T. Sethi, T. Integrins and extracellular matrix: a novel mechanism of multidrug resistance. Expert Rev Anticancer Ther 2002 2 : 449 459.
8. Perloff, MD, et al. Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes. Biochem Pharmacol 1999 57 : 1227 1232.
9. Shabbits, JA, et al. Molecular and pharmacological strategies to overcome multidrug resistance. Expert Rev Anticancer Ther 2001 1 : 585 594.
10. Tsuruo, T, et al. Molecular targeting therapy of cancer: drug resistance apoptosis and survival signal. Cancer Sci 2003 94 : 15 21.
11. Bardelmeijer, HA, et al. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Investig New Drugs 2004 22 : 219 229.
12. Barthomeuf, C, et al. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin. Cancer Chemother Pharmacol 2005 56 : 173 181.
13. 3. Biochem Pharmacol 2003 65 : 75 82.
14. Kitagawa, S, et al. Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells. J Pharm Pharmacol 2004 56 : 1001 1005.
15. McKellar, QA. Benchaoui, HA. Avermectins and milbemycins. J Vet Pharmacol Ther 1999 19 : 331 351.
16. Wolstenholme, AJ. Rogers, AT. Glutamate-gated chloride channels and the mode of action of the avermectin/milbemycin anthelmintics. Parasitology 2005 131 : S85 S95.
17. Korystov, YN, et al. Avermectins inhibit multidrug resistance of tumor cells. Eur J Pharmacol 2004 493 : 57 64.
18. Molyneux, DH, et al. Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends Parasitol 2003 19 : 516 526.
19. Dider, A. Loor, F. The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor. Anticancer Drugs 1996 7 : 745 751.
20. Pouliot, JF, et al. Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem Pharmacol 1997 53 : 17 25.
21. Lespine, A, et al. Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3). Chem Biol Interact 2006 159 : 169 179.
22. Lespine, A, et al. Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship. Eur J Pharm Sci 2007 30 : 84 94.
23. Ji, BS, et al. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells. J Pharm Pharmacol 2007 59 : 1011 1015.
24. Kitagawa, S, et al. Inhibition of P-glycoprotein function by tannic acid and pentagalloylglucose. J Pharm Pharmacol 2007 59 : 965 969.
25. Chen, LM, et al. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. J Pharm Pharmacol 2004 56 : 1061 1066.
26. Qian, F, et al. Modulation of P-glycoprotein function and reversal of multidrug resistance by (-)-epigallocatechin gallate in human cancer cells. Biomed Pharmacother 2005 59 : 64 69.
27. Shi, YQ, et al. Reversal effect of a macrocyclic bisbibenzyl plagiochin E on multidrug resistance in adriamycin-resistant K562/A02 cells. Eur J Pharmacol 2008 584 : 66 71.
28. Li, J, et al. Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line. Breast Cancer Res 2001 3 : 253 263.
29. Yu, ST, et al. Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochem Biophys Res Commun 2007 358 : 79 84.
30. Zheng, LH, et al. Cantharidin reverses multidrug resistance of human hepatoma HepG2/ADM cells via down-regulation of P-glycoprotein expression. Cancer Lett 2008 272 : 102 109.